Find
News Releases
| All | ||||||
|---|---|---|---|---|---|---|
 |
Johnson & Johnson Reports 2011 Fourth-Quarter and Full-Year Results: Jan 24, 2012 |
80.1 KB |
|
|||
|
NEW BRUNSWICK, N.J., Jan. 24, 2012 /PRNewswire-FirstCall/ -- Johnson & Johnson today announced sales of $16.3 billion for the fourth quarter of 2011, an increase of 3.9% as compared to the fourth quarter of 2010. Operational sales increased 4.0% and the negative impact of currency was 0.1%. Domestic sales declined 3.4%, while international sales in... |
||||||
|
Johnson & Johnson to Host Analyst Meeting to Discuss Fourth-Quarter and Full-Year 2011 Financial Results Jan 17, 2012 |
6.1 KB |
|
|||
|
NEW BRUNSWICK, N.J., Jan. 17, 2012 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) will host an analyst meeting at 8:30 a.m. (Eastern Time) on Tuesday, Jan. 24, to discuss fourth-quarter and full-year 2011 financial results. The meeting will be hosted by William C. Weldon, Chairman of the Board and Chief Executive Officer; Dominic J. Carus... |
||||||
|
Johnson & Johnson Announces First-Quarter 2012 Quarterly Dividend Jan 3, 2012 |
5.7 KB |
|
|||
|
NEW BRUNSWICK, N.J., Jan. 3, 2012 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first-quarter of 2012 of $0.57 per share on the company's common stock. The dividend is payable on March 13, 2012, to shareholders of record at the close of business on Feb. 28, 2012. The ... |
||||||
|
Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome Dec 29, 2011 |
222.4 KB |
|
|||
|
RARITAN, DECEMBER 29, 2011 - Janssen Research & Development, LLC (JRD) announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of XARELTO® (rivaroxaban), an oral anticoagulant, to reduce the risk of (throm... |
||||||
|
Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765 Dec 8, 2011 |
9.6 KB |
|
|||
|
HORSHAM, Pa., Dec. 8, 2011 /PRNewswire-FirstCall/ -- Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ), announced today that it has executed an agreement with Pharmacyclics, Inc. (Nasdaq: PCYC) to jointly develop and market the anti-cancer compound, PCI-32765. A number of Phase 1 and 2 studies with... |
||||||
|
Johnson & Johnson to Participate in the Piper Jaffray 23rd Annual Health Care Conference Nov 28, 2011 |
5.8 KB |
|
|||
|
NEW BRUNSWICK, N.J., Nov. 28, 2011 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Piper Jaffray 23rd Annual Health Care Conference on Tuesday, Nov. 29th at The New York Palace, New York, NY. Gary Pruden, Company Group Chairman, Ethicon will present in a session scheduled at 8:00 a.m. (Eastern Time). The webcast ... |
||||||
|
EDURANT® (Rilpivirine) Approved in Europe for Treatment-Naïve Adults with HIV-1 Infection with a Baseline Viral Load ≤ 100,000 HIV-1 RNA Copies/mL Nov 28, 2011 |
106.4 KB |
|
|||
|
Beerse, Belgium, 28 November 2011 - Janssen International NV announced today that the European Commission (EC) has granted marketing authorisation for EDURANT® (rilpivirine) as a once daily treatment in combination with other antiretroviral agents (ARVs), for the treatment of human immunodeficiency virus type 1 (HIV-1) i... |
||||||
|
Landmark Study Shows that Adding Rivaroxaban to Standard Antiplatelet Therapy Significantly Reduced Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome Nov 13, 2011 |
20.9 KB |
|
|||
|
ORLANDO, NOVEMBER 13, 2011 - Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced today that adding oral rivaroxaban to standard antiplatelet therapy significantly reduced the composite primary efficacy endpoint of cardiovascular-related deaths, heart attacks or strokes in patients with acute coro... |
||||||
|
Ethicon Endo-Surgery Receives 510(K) Clearance for New ENSEAL® G2 Curved and Straight Tissue Sealers Line--Broadest Range of Advanced Bipolar Tissue Sealers Available for Open and Minimally Invasive Surgery Nov 10, 2011 |
7.6 KB |
|
|||
|
CINCINNATI - November 10, 2011 -Ethicon Endo-Surgery, Inc. (EES) today announces U.S. FDA 510(k) clearance of their innovative ENSEAL® G2 Curved and Straight Tissue Sealers line to expand surgeons' options for achieving strong vessel seals while remaining gentle on tissue in both open and minimally invasive surgery . This line of eight new t... |
||||||
|
New Sirukumab (CNTO 136) Phase 2 Data Show Efficacy of Interleukin-6 Inhibitor Across Multiple Dose Regimens in Treatment of Rheumatoid Arthritis Nov 7, 2011 |
14.2 KB |
|
|||
|
CHICAGO, Nov. 7, 2011 /PRNewswire/ -- Results from Part B of a two-part Phase 2 study of sirukumab (CNTO 136), a subcutaneously administered human antibody directed against the cytokine interleukin (IL)-6, showed that patients with active rheumatoid arthritis (RA) receiving the monoclonal antibody demonstrated substantial improvement in signs and s... |
||||||
|
INCIVO® (Telaprevir) Demonstrates Efficacy and Increased Cure Rates among Cirrhotic Patients with Genotype-1 Chronic HCV Compared to Standard of Care Nov 5, 2011 |
15.5 KB |
|
|||
|
San Francisco, United States, 5th November 2011 - Janssen Pharmaceutica NV (Janssen), today presented new data for INCIVO® (telaprevir) at the American Association for the Society of Liver Disease (AASLD) Annual Meeting, highlighting the safety and efficacy of a telaprevir based regimen in cirrhotic patients who had previously fail... |
||||||
|
Tibotec to present final safety and efficacy results from phase 2b PILLAR study of Once-daily TMC435 in late-breaker at AASLD Nov 5, 2011 |
49.4 KB |
|
|||
|
[San Francisco, CA. Saturday 5th November 2011] – Tibotec Pharmaceuticals (Tibotec), one of the Janssen (Janssen) Pharmaceutical Companies, today will present results of the final analysis of PILLAR, a phase 2b study of the investigational hepatitis C virus (HCV) NS3/4A protease inhibitor TMC435 in treatment-naïve patients with chronic ge... |
||||||
|
Ethicon-Endo Surgery Completes Acquisition of SterilMed Nov 4, 2011 |
8.4 KB |
|
|||
|
CINCINNATI - November 4, 2011 - Ethicon Endo-Surgery, Inc. (EES), a global leader in the development of innovative medical devices for minimally invasive and open surgical procedures, today announced the closing of the transaction to acquire SterilMed, Inc. (SterilMed), a leader in the reprocessing and remanufacturing of single-use medica... |
||||||
|
FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation Nov 4, 2011 |
25.3 KB |
|
|||
|
RARITAN, NJ, November 4, 2011 - Janssen Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved XARELTO® to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. XARELTO® is the only oral anticoagulant approved in the U.S. that offers once-daily d... |
||||||
|
Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain Oct 31, 2011 |
24.8 KB |
|
|||
|
TITUSVILLE, N.J., Oct. 31, 2011 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for NUCYNTA® ER (tapentadol) extended-release tablets, an oral analgesic, for the ... |
||||||
|
Johnson & Johnson Announces Fourth-Quarter 2011 Quarterly Dividend Oct 21, 2011 |
5.7 KB |
|
|||
|
NEW BRUNSWICK, N.J., Oct. 21, 2011 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2011 of $0.57 per share on the company's common stock. The dividend is payable on Dec. 13, 2011, to shareholders of record at the close of business on Nov. 29, 2011. The... |
||||||
|
FDA Approves Label Update for PREZISTA® to Include 192-Week Data in HIV-1-Infected Adult Patients Starting Treatment Oct 21, 2011 |
14.0 KB |
|
|||
|
TITUSVILLE, N.J., Oct. 21, 2011 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP, announced today that the U.S. Food and Drug Administration (FDA) has approved a label update for PREZISTA®(darunavir) tablets to include 192-week data from the ARTEMIS study. ARTEMIS evaluated the efficacy and... |
||||||
|
Johnson & Johnson Reports 2011 Third-Quarter Results Oct 18, 2011 |
55.5 KB |
|
|||
|
NEW BRUNSWICK, N.J., Oct. 18, 2011 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $16.0 billion for the third quarter of 2011, an increase of 6.8% as compared to the third quarter of 2010. Operational results increased 2.6% and the positive impact of currency was 4.2%. Domestic sales declined 3.7%. International... |
||||||
|
Johnson & Johnson to Host Analyst Conference Call on Third-Quarter Results Oct 11, 2011 |
6.0 KB |
|
|||
|
NEW BRUNSWICK, N.J., Oct. 11, 2011 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) will host a conference call for financial analysts at 8:30 a.m. (Eastern Time) on Tuesday, October 18, 2011, to review third-quarter results. Dominic Caruso, Vice President, Finance and Chief Financial Officer, and Louise Mehrotra, Vice President, Investor R... |
||||||
|
Scios Inc. Announces Agreement with Department of Justice Regarding NATRECOR® Oct 5, 2011 |
6.4 KB |
|
|||
|
RARITAN, N.J., Oct. 5, 2011 /PRNewswire/ -- Today Scios Inc. announced an agreement with the United States Department of Justice to resolve allegations of misbranding of NATRECOR® (nesiritide), a prescription medication for patients with heart failure. As part of this agreement, Scios Inc. entered a guilty plea to a single misdemeanor violati... |
||||||
|
||||||
= add release to Briefcase